Women's oncology market will reach $110B by 2030 across therapeutics, diagnostics and care delivery

The women's oncology market is poised for substantial growth, projected to reach between $100 billion and $110 billion by 2030, according to a report by PwC. This expansion will occur across various sectors, including therapeutics, diagnostics, medical devices, and care delivery, driven by advancements in precision medicine, early detection technologies, and integrated care models, as well as new therapeutics.

The report focuses on women-specific cancers, including breast, ovarian, endometrial, cervical, vulvar, and vaginal cancers. While breast cancer has received consistent funding and interest, other women's cancers, such as ovarian, endometrial, and cervical cancers, remain underfunded and underserved. The National Institutes of Health research funding for these cancers is significantly skewed towards breast cancer, with ovarian cancer receiving approximately $43,000 per death compared to nearly $70,000 for breast cancer.

Endometrial, vulvar, and vaginal cancers also remain underfunded and underserved. There are gaps in cervical cancer care, particularly in preventive screening and vaccination for younger and underserved women. Improved survival rates of younger female cancer patients have increased interest in care beyond treatment, such as quality of life treatments and fertility preservation.

Physicians are developing oncofertility programs, while working to reduce cost barriers due to lack of coverage. Early detection remains a key area with significant unmet needs, particularly in ovarian cancer, where early detection is crucial to five-year survival rates. Reducing barriers to preventive care is essential, and some companies are addressing this by bringing screening closer to patients through mobile mammography programs and at-home cervical cancer tests.

The market for women's oncology solutions is diverse, with about 70% of the market value coming from the pharmaceutical industry, led by breast cancer advances. Other sectors, such as device and diagnostics companies, are also integrating AI into their practices by adding it to standard clinical workflows and screenings. Investment opportunities exist in various areas, including fertility preservation, mental health, endocrine management, supportive services, and oncology survivorship.

Payers, employers, and consumer health companies must also focus on reimbursement for outcomes, navigation and care coordination benefits, and developing tools that serve the patient's entire treatment arc.